Boston, Massachusetts--(Newsfile Corp. - June 7, 2023) - hC Bioscience announced its tRNA-based therapy demonstrated proof-of-concept in an in vivo model of metastatic colorectal cancer with 75% tumor growth inhibition. This is the first report of a tRNA-based therapeutic showing feasibility in an in vivo cancer model, marking a significant milestone for tRNA-based therapies. The data showed that tRNA, engineered by hC Bioscience, can recognize and repair disease-causing nonsense mutations (premature stop codons) and produce functional, full-length tumor suppressor proteins. Because nonsense mutations drive an estimated 10-15% of cancers, tRNA-based therapy represents a potential new modality for the treatment of cancer.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• hC Bioscience's engineered tRNA demonstrated preclinical proof-of-concept in metastatic colorectal cancer, paving the way for treating cancer with tRNA-based therapy.
• The tRNA-based therapy was engineered to overcome premature stop codons, which drive an estimated 10-15% of cancers.
• The data demonstrated 75% tumor growth inhibition of colorectal tumor and restoration of full-length tumor suppressor proteins in vivo as well as dose-dependent response in vitro.

Click image above to view full announcement.

hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience's innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.

Contacts:

Savannah Beaver
(617) 804-0366
savannah@reportablenews.com

Source: hC Bioscience

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/169093